Armas and Micro Labs Announce Collaboration To Launch Generic Injectables to U.S. Market

Wednesday, May 29, 2019

Armas Pharmaceuticals Inc. and Micro Labs USA, Inc. have announced today, the forming of a strategic collaboration to bring select multisource injectable products to the U.S. market. The first product, Diphenhydramine Injection 50mg/1mL, is slated to be launched in May. Diphenhydramine has been seen on the FDA Drug Shortage list since September of 2018. Additional product launches are set for the second quarter of 2019. The market size of these products total $100 million annually, according to IMS data.

"Armas Pharmaceuticals is excited to partner with Micro Labs as we look to expand our product line across multiple therapeutic classes," said John Niemi, President and CEO of Armas. "Our first launch with Micro Labs, Diphenhydramine Injection 50mg/1mL, is a medicinal drug used widely in the healthcare space. It is our aim to make this product available at affordable pricing to patients in need of the same. This medication reinforces our ultimate goal to bring high quality, affordable drugs that are needed in the U.S. market."

Ashok Jain, Director of Micro Labs USA, Inc. said, "Micro and Armas have been working together on various ideas and projects. We are proud to be associated with Armas and we truly value the rich experience and understanding of the US healthcare sector they bring to the partnership."